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Rationale: Hypercapnic respiratory failure because of inspiratory
muscle weakness is the most important cause of death in chronic
obstructive pulmonary disease (COPD). However, the pathophysiol-
ogy of failure of the diaphragm to generate force in COPD is in
part unclear. Objectives: The present study investigated contractile
function and myosin heavy chain content of diaphragm muscle
single fibers from patients with COPD. Methods: Skinned muscle
fibers were isolated from muscle biopsies from the diaphragm of
eight patients with mild to moderate COPD and five patients with-
out COPD (mean FEV1 % predicted, 70 and 100%, respectively).
Contractile function of single fibers was assessed, and afterwards,
myosin heavy chain content was determined in these fibers. In
diaphragmmuscle homogenates, the level of ubiquitin-protein con-
jugation was determined. Results: Diaphragm muscle fibers from
patients with COPD showed reduced force generation per cross-
sectional area, and reduced myosin heavy chain content per half
sarcomere. In addition, these fibers had decreased Ca2 sensitivity
of force generation, and slower cross-bridge cycling kinetics. Our
observationswere present in fibers expressing slow and2A isoforms
ofmyosin heavy chain. Ubiquitin-protein conjugationwas increased
in diaphragmmuscle homogenates of patients with mild to moder-
ate COPD. Conclusions: Early in the development of COPD, dia-
phragm fiber contractile function is impaired. Our data suggest that
enhanced diaphragm protein degradation through the ubiquitin-
proteasome pathway plays a role in loss of contractile protein and,
consequently, failure of the diaphragm to generate force.
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Chronic obstructive pulmonary disease (COPD) has been pre-
dicted to become the third leading cause of death and the fifth
commonest cause of disability in the world by 2020 (1). Hyper-
capnic respiratory failure because of inspiratory muscle weak-
ness (2) is the most important cause of death in COPD (3), and
maximum inspiratory pressure is an independent determinant
of survival in these patients (4).
The diaphragm is the most important inspiratory muscle. In
severeCOPD, the diaphragmundergoes a fiber-type shift toward
more fatigue-resistant fibers (5, 6). In addition, changes in sar-
comere length, mitochondrial density, and enzyme activity occur
within diaphragmmuscle fibers of these patients (7, 8). However,
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no conclusive studies have been published on direct contractile
properties of the diaphragm of healthy subjects and patients with
COPD. Consequently, the pathophysiology of failure of the dia-
phragm to generate force in COPD is in part unclear.
Muscle force is generated by cross bridges, which are formed
by myosin heavy chain heads that attach to actin filaments (9).
Force-generating capacity of single muscle fibers depends on
contractile protein content of the fiber (10). Loss of skeletal
muscle mass occurs in cachexia-associated conditions, such as
cancer, AIDS, and congestive heart failure (11). There is growing
evidence that, under cachectic conditions, cytokines initiate muscle
wasting and inducemuscle atrophy throughactivationof theubiqui-
tin–proteasome pathway, by selectively targeting myosin (12).
The present study investigated contractile function of dia-
phragm muscle single fibers from patients with COPD. We hy-
pothesized that, in patients with mild to moderate COPD (Global
Initiative for Chronic Obstructive Lung Disease [GOLD] stage
I/II), diaphragm single-fiber contractile function is impaired. In
addition, it was hypothesized that loss of myosin in these fibers
contributes to the reduction in contractile performance. On the
basis of previous observations (12), we hypothesized that protein
ubiquitination is enhanced in the diaphragm of these patients
compared with patients without COPD.
Some of the results of these studies have been previously
reported in the form of an abstract (13).
METHODS
Subjects and Pulmonary Function Testing
Diaphragm muscle biopsies were obtained from eight patients with
COPD (six men) and five patients without COPD (three men). Biopsies
of the right anterior costal diaphragm were obtained during thoracot-
omy for lung cancer (stage T1–3 N0–1 MX in both groups). Patients
with more than 10% weight loss in the last 6 months before surgery
were excluded from the study. General characteristics and pulmonary
function data are shown inTable 1. Informed consent was obtained from
each subject. The study was approved by the local ethics committee.
Diaphragm Biopsies
The fresh biopsy specimen was divided in two parts: one part for deter-
mination of single-fiber contractile properties and the other part for
ubiquitin-conjugation analysis. Both parts were processed and stored
as presented in the online supplement.
Tissue Preparation and Single-Fiber Dissection
Approximately 1 hour before determination of single-fiber contractile
properties, the muscle bundle was transferred to cold (5C) relaxing
solution containing 1% Triton X-100 to permeabilize the plasma mem-
brane. From the muscle bundle, segments of single fibers of approxi-
mately 2 mm were isolated. Subsequently, the fiber ends were attached
to aluminum foil clips, and mounted on the single-fiber apparatus.
Fibers that appeared injured (e.g., sarcolemmal damage, loss of cross-
striation, or other irregularities) during microscopic examination (400
magnification) were excluded from the study.
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Single-Fiber Contractile Measurements
The compositions of activating and relaxing solutions used for contrac-
tile measurements were reported previously (14), and are presented in
the online supplement. Force generation, the fraction of strongly
attached cross bridges and the rate constant of force redevelopment
were determined in the single fibers during maximal Ca2 activation. In
addition, Ca2 sensitivity of single-fiber force generation was recorded.
Single-fiber contractile measurements and experimental protocol were
performed according to previously described methods (15, 16), with
minor modifications, and are presented in the online supplement.
Myosin Heavy Chain Isoform Composition Determination
At the end of the single-fiber contractile measurement protocol, myosin
heavy chain isoform composition of the fiber was identified by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis, as described pre-
viously (14), with minor modifications (17). Our methodology is pre-
sented in the online supplement.
Myosin Heavy Chain Content per
Half-Sarcomere Measurements
Myosin heavy chain content per half sarcomere in the same single fibers
was determined (18), as presented in the online supplement.
Assay of Ubiquitin-Protein Conjugates
The methodology for determination of content of ubiquitin-protein
conjugates in diaphragm muscle is presented in the online supplement.
Statistical Methods
Differences within parameters describing single-fiber characteristics
and contractile properties were tested using a random intercept mixed
linear model for repeated measurements with group (COPD or non-
COPD) as fixed factor. The model was used to predict the individual
(fiber) measurements. Thereafter, residuals were calculated (observed
minus expected value) to verify the model assumption that these residu-
als follow a normal distribution. Model estimates of mean values were
computed per group. To evaluate statistical significance of difference be-
tween patients with and without COPD regarding ubiquitin-conjugation
data, a t test was used. Two-sided level of significance was fixed at 5%.
Because the present study was explorative and not confirmative, of
nature, no correction was necessary for type I errors.
RESULTS
Subject Characteristics
Subject characteristics and pulmonary function data are shown
in Table 1. On the basis of GOLD classification (19, 20), two
patients had mild COPD (stage I) and the others were classified
as moderate COPD (stage II). The patients with COPD were
comparable to the patients without COPD with respect to age,
body mass index, PaO2, and PaCO2.
TABLE 1. PATIENT CHARACTERISTICS
Non-COPD (n  5 ) COPD (n  8 )
Male/female 3/2 6/2
Age, yr 59  4 (46–72) 60  4 (42–75)
BMI, kg/m2 28  2 (22–33) 28  2 (21–36)
FEV1, % predicted 100  3 (95–110) 70  4 (51–94)
VC, % predicted 103  6 (87–121) 89  9 (40–128)
FEV1/VC, % 75  3 (70–86) 58  3 (44–69)
TLC, % predicted 99  5 (84–116) 105  6 (77–125)
DLCO/VA, % predicted 103  8 (88–135) 87  7 (54–110)
PaO2, kPa 10.9  0.8 (8.9–13.3) 11.0  0.5 (8.3–12.6)
PaCO2, kPa 5.2  0.1 (4.9–5.6) 5.2  0.2 (3.8–5.7)
Definition of abbreviations: BMI bodymass index; COPD chronic obstructive
pulmonary disease; DLCO/VA  carbon monoxide transfer coefficient per alveolar
volume; TLC  total lung capacity; VC  vital capacity.
Values are means  SEM with range (in parentheses).
Diaphragm Muscle Single-Fiber Data
A total of 227 single fibers from patients with andwithout COPD
were used for contractile measurements. These fibers expressed a
single myosin heavy chain isoform (110 myosin heavy chain slow
fibers and 117 myosin heavy chain 2A fibers). Fibers that coex-
pressed myosin heavy chain slow and 2A (n  20), or myosin
heavy chain 2Aand2X(n 2)were excluded from further analysis.
Because of technical circumstances, in some fibers not all parame-
ters describing contractile properties or parameters based on myo-
sin heavy chain quantification could be determined. Therefore, the
number of single fibers analyzed can differ per parameter.
Maximum force per cross-sectional area. Usually, maximum
force generation in single fibers is normalized to fiber cross-
sectional area, assuming that increases in cross-sectional area
parallel increased myosin content. Single-fiber cross-sectional
area was not significantly different between patient groups (3.9 
0.4 · 103 and 3.1  0.5 · 103 mm2 for type slow (p  0.19) and
3.5  0.5 · 103 and 3.5  0.6 · 103 mm2 for type 2A fibers
(p  0.98); patients with COPD and without COPD, respec-
tively). Maximum force, normalized to cross-sectional area, of
single fibers from patients with COPD was lower in type slow
(p  0.001) and 2A fibers (p  0.008), respectively, compared
with patients without COPD (Figure 1).
Myosin heavy chain concentration. Myosin heavy chain con-
centration in single fibers from patients with COPD was signifi-
cantly lower compared with those from patients without COPD
in both fiber types (p  0.001; Figure 2A).
Myosin heavy chain content per half sarcomere. Myosin heavy
chain content in the single fibers normalized to half sarcomere
volume reflects the number of cross bridges in parallel in the
single fibers, independent of cross-sectional area (21). Figure 2B
shows that, in patients with COPD, compared with those without
COPD, myosin heavy content per half sarcomere is significantly
reduced in type slow (p  0.018) and 2A fibers (p  0.002).
Force per half sarcomere myosin heavy chain content. Maxi-
mum force values of single fibers were normalized to myosin
heavy chain content per half sarcomere to evaluate the effect
of cross-bridge number on maximum force per cross-sectional
area. Figure 3 shows that maximum force in both fiber types
was similar in patients with and without COPDwhen normalized
for myosin heavy chain content (type slow fibers, p  0.15; type
2A fibers, p  0.63).
Fraction of cross bridges in strongly attached state. Maximum
force depends on the fraction of cross bridges in the strongly
Figure 1. Single-fiber maximum force per cross-sectional area in type
slowand 2A fibers frompatientswith (solid bars) andwithout (white bars)
chronic obstructive pulmonary disease (COPD). The numbers above the
bars represent the total number of single fibers analyzed. Data are
presented as model estimates  SEM. *p  0.05 difference from group
without COPD.
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Figure 2. (A ) Myosin heavy chain concentration in type slow and 2A
fibers from patients without COPD (white bars) and those with COPD
(solid bars). Myosin heavy chain concentration was determined from
sodium dodecyl sulfate–polyacrylamide gel electrophoresis densitome-
try of single fibers and fiber volume. (B ) Myosin heavy chain content
per half sarcomere in type slow and 2A fibers from patients without
COPD (white bars) and those with COPD (solid bars). Myosin heavy
chain content per half sarcomere was determined from single-fiber
myosin heavy chain concentration and half-sarcomere volume. Myosin
heavy chain content per half sarcomere estimates the number of cross
bridges in parallel per single fiber. The numbers above the bars represent
the total number of single fibers analyzed. Data are presented as model
estimates  SEM. *p  0.05 difference from group without COPD.
attached state. This can be derived from measuring single-fiber
stiffness (10). Figure 4 shows that, in both type slow (p  0.62)
and 2A (p  0.37) fibers, the fraction of strongly attached cross
bridges at maximum activation was not significantly different
between patient groups.
Cross-bridge cycling kinetics. The rate constant of force rede-
velopment was used as a measure for cross-bridge cycling kinet-
ics (10). The maximally activated fiber was rapidly released to
a shorter length, and then rapidly restretched. During this proce-
dure, all cross bridges detach and force decreases abruptly to
zero. Subsequently, force redevelops as cross bridges reattach
to actin. Figure 5 shows that, in diaphragm muscle fibers from
patients with COPD, the rate constant of force redevelopment
at maximum activation was slower in both type slow (p  0.03)
and type 2A fibers (p 0.01) than in fibers from patients without
COPD. As expected, rate constant of force redevelopment was
faster in type 2Afibers than in type slowfibers within both patients
without COPD (p  0.001) and those with COPD (p  0.001).
Myofibrillar Ca2 sensitivity. Ca2 sensitivity of force genera-
tion in diaphragm muscle fibers is reduced in patients with
COPD, as can be derived from the rightward shift of the force–pCa
curves for both type slow and 2A fibers (Figures 6A and 6B,
respectively). In slow fibers, pCa50 was 5.95  0.10 versus 6.32 
0.11 in patients with and without COPD, respectively (p  0.02).
Figure 3. Maximum force per half sarcomere myosin heavy chain con-
tent in type slow and 2A fibers from patients without COPD (white bars)
and those with COPD (solid bars). Maximum force normalized for half-
sarcomere myosin heavy chain content estimates the average force
generated per cross bridge. The numbers above the bars represent the
total number of single fibers analyzed. Data are presented as model
estimates  SEM.
In type 2A fibers, pCa50 was 5.68  0.06 versus 5.94  0.06 in
patients with and without COPD, respectively (p  0.007).
Ubiquitin-Protein Conjugation
Ubiquitin-protein conjugation marks the substrate protein for
proteasomal degradation. Figure 7 shows increased ubiquitin-
protein conjugation in diaphragm muscle homogenates of pa-
tients with COPD compared with those without COPD. Total
optical density of ubiquitin-protein conjugates in diaphragm
muscle homogenates was higher in patients with COPD com-
pared with patients without COPD (Figure 7A; p  0.02). The
antiubiquitin immunoblot of diaphragm muscle homogenates
from patients with and without COPD showed the appearance
of additional ubiquitin-protein conjugates withmolecular masses
between approximately 75 and 250 kD in diaphragm muscle
homogenates from patients with COPD (Figure 7B). Also, op-
tical density of ubiquitin–protein conjugates with molecular
masses of approximately 30 and approximately 70 kD, present
in diaphragmmuscle homogenates frompatients without COPD,
was increased in diaphragm muscle homogenates from patients
with COPD (Figure 7B).
Figure 4. Fraction of strongly attached cross bridges at maximal activa-
tion in type slow and 2A fibers from patients without COPD (white bars)
and those with COPD (solid bars). The fraction of strongly attached
cross bridges was estimated by determining the ratio of single-fiber
stiffness at maximal activation in the presence of adenosine triphos-
phate to stiffness at maximal activation in the absence of adenosine
triphosphate. The numbers above the bars represent the total number
of single fibers analyzed. Data are presented as model estimates SEM.
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Figure 5. Rate constant of force redevelopment at maximal activation
in type slow and 2A fibers from patients without COPD (white bars)
and those with COPD (solid bars). The rate constant of force redevelop-
ment was used as a measure for cross-bridge cycling kinetics. The num-
bers above the bars represent the total number of single fibers analyzed.
Data are presented as model estimates  SEM. *p  0.05 difference
from group without COPD within fiber type; #p  0.05 difference from
type slow fibers within patient group.
DISCUSSION
Our results clearly demonstrate that diaphragm muscle single
fibers from patients with COPD have reduced force-generating
capacity, concomitant with loss of myosin heavy chain in these
specific fibers. In the diaphragm of these patients with COPD,
elevated levels of ubiquitin–conjugated proteins were found, sug-
gesting accelerated muscle protein degradation. In addition to
loss of contractile protein, the remaining contractile proteins in
these fibers are dysfunctional because cross-bridge cycling was
slower. Also, the calcium sensitivity of force generation is re-
duced in single fibers from patients with COPD, which could
contribute to muscle weakness at submaximal activation. Impor-
tantly, these changes appear to occur in patients with only mild
to moderate COPD (GOLD stage I/II).
Reduced Maximum Force Generation in Diaphragm Muscle
Single Fibers in COPD
The present study shows reduced maximum force generation in
diaphragm single fibers from patients with COPD (see Figure 1).
Maximum force generation in permeabilized single fibers is de-
termined by the following factors: (1) myosin heavy chain con-
tent per half sarcomere, (2) force generated per half sarcomere
myosin heavy chain content, and (3) the fraction of strongly
attached cross bridges (10). Therefore, the reduced force genera-
tion in single fibers from patients with COPD should be reflected
by a change in one or more of its determinants. Our results show
a decrease in myosin heavy chain content per half sarcomere in
patients with COPD in both type slow and 2A fibers (see Figure
2B). The magnitude of the decrease of myosin heavy chain con-
tent can completely explain the reduced force generation in
these fibers. In line with previous findings, the other two determi-
nants of force generation, force generated per half sarcomere
myosin heavy chain content and the fraction of strongly attached
cross bridges, were not different between single fibers from pa-
tients with andwithout COPD (see Figures 3 and 4, respectively).
Although diaphragm function in vivo is also determined by other
factors (e.g., neural drive, muscle fiber recruitment, calcium ho-
meostasis), our results strongly indicate that loss of myosin is a
key player in the etiology of diaphragm muscle weakness in
COPD. Only one previous study has reported changes in dia-
phragm single-fiber contractile properties in patients withCOPD
(22). That study showed that, in two patients with severe COPD,
Figure 6. Force–Ca2 characteristics of single fibers from three patients
without COPD and four with COPD. Isometric force generated in re-
sponse to incubation of single fibers with incremental [Ca2] was deter-
mined. Note the rightward shift of the force–Ca2 relationship in both
type slow (panel A) and 2A (panel B) single fibers from patients with
COPD.Calciumconcentration needed for 50%ofmaximal force genera-
tion was significantly higher (i.e., lower pCa50, see RESULTS) in both fiber
types from patients with COPD compared with patients without COPD,
indicating decreased Ca2 sensitivity of force generation. Data are pre-
sented as model estimates SEM. n 19 for patients with and without
COPD, respectively, for type slow fibers; n  10 for patients with and
without COPD, respectively, for type 2A fibers. Triangles indicate pa-
tients without COPD; squares indicate patients with COPD. MHC 
myosin heavy chain.
maximum force per cross-sectional area was reduced in single
fibers. However, myosin content was not determined, thus the
underlying pathophysiology remained unclear.
In vivo, the diaphragm does not perform maximum isometric
contractions but shortens against a submaximal load. Thus, sub-
maximal and kinetic parameters ofmuscle function providemore
physiologic information. Ca2 sensitivity of force generation is
determined by binding of Ca2 to troponin C, which in turn affects
the probability of myosin binding to actin, or cross-bridge forma-
tion. The rightward shift of the force–pCa curve (see Figure 6)
indicates that, at a certain Ca2 concentration, generated force
relative to maximum force is reduced in fibers from patients
with COPD. In other words, Ca2 sensitivity of force generation
is reduced. This appears to be an important finding, because it
could compromise diaphragm function at submaximum activa-
tion, which reflects in vivo activation of the diaphragm. The rate
constant of force redevelopment is determined by the rate of
cross-bridge formation and detachment (23). The decreased rate
constant of force redevelopment in diaphragm fibers from pa-
tients with COPD (see Figure 5) shows that cross-bridge cycling
kinetics are impaired in the diaphragm in COPD. These data
show that, besides loss of contractile protein in the diaphragm
in COPD, the remaining contractile proteins are dysfunctional.
The nature of these dysfunctional proteins is unclear. However,
myosin and troponin might be involved, because function of
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Figure 7. Ubiquitin–protein conjugation in diaphragm muscle homog-
enates of patients with COPD (n  7) compared with the patients
without COPD (n  5). (A ) Total optical density of ubiquitin–protein
conjugates in diaphragm muscle homogenates. Data are presented as
mean  SEM. *p  0.05 difference from group without COPD. (B )
Antiubiquitin immunoblot of diaphragm muscle homogenates from
patientswith andwithout COPD. Each lane shows result for a diaphragm
muscle homogenate from one patient. Molecular weight markers are
shown in kilodaltons. Note the appearance of additional ubiquitin-
protein conjugates with molecular masses between approximately 75
and 250 kD in diaphragm muscle homogenates from patients with
COPD. Also, optical density of ubiquitin–protein conjugates withmolec-
ular masses of approximately 30 and approximately 70 kD, present in
diaphragm muscle homogenates from patients without COPD, was
increased in diaphragmmuscle homogenates from patients with COPD.
these proteins is an important determinant of cross-bridge cy-
cling kinetics and Ca2 sensitivity of force generation.
What Might Cause the Loss of Myosin Heavy Chain in the
Diaphragm of Patients with COPD?
The present study is the first to investigate levels of ubiquitin-
conjugated proteins in human diaphragm muscle. We found
elevated levels of ubiquitin-conjugated proteins in diaphragm
muscle of patients with COPD compared with those without
COPD (see Figure 7). Ubiquitin conjugation to proteins marks
the proteins for proteasomal degradation as ubiquitin accumu-
lates (24). It is well recognized that the ubiquitin–proteasome
pathway, and not lysosomal or Ca2-activated proteinases, de-
grade myofibrillar proteins, such as actin and myosin (24–27).
Our findings suggest involvement of the ubiquitin–proteasome
proteolytic pathway in the loss of myosin in the diaphragm of
patients with COPD.
Recently, Chamberlain (12) addressed the role of selective
degradation of myosin by the ubiquitin–proteasome pathway in
cachexia. Cytokines may be at play (12). Resistive breathing has
been shown to increase expression of cytokines, such as tumor
necrosis factor  and interleukin 6, in the diaphragm (28). Also,
circulating levels of these cytokines are increased in a subgroup
of patients with COPD (29, 30), supporting a role for pro-
inflammatory cytokines in diaphragmweakness. In our study, the
loss of myosin heavy chain in single fibers from patients with
COPD is not paralleled by decreased fiber cross-sectional area.
Consequently, myosin heavy chain concentration is decreased
in these muscle fibers (see Figure 2A). Because preferential
loss of myosin heavy chain would increase the average distance
between myosin and actin filaments, this might induce muscle
atrophy later in the course of the disease (i.e., decreased fiber
cross-sectional area) to restore filament lattice spacing needed
for optimal contractile function (12). Although speculative, our
findings could support the hypothesis that, in mild to moderate
COPD, loss of myosin heavy chain is an initial, but functional
important step in diaphragm muscle fiber atrophy, as observed
in severe COPD (6, 7). Therefore, ubiquitin-induced loss of
myosin heavy chain in the diaphragm may play a role in ventila-
tory failure in severe COPD.
In summary, the present study clearly demonstrates reduced
force-generation capacity in single diaphragmmuscle fibers from
patients with COPD. The reduced force generation in these fibers
can be explained by loss of myosin heavy chain. Diaphragm
muscle frompatientswithCOPDhad increased levels of ubiquitin-
conjugated proteins, suggesting accelerated muscle protein deg-
radation. The remaining contractile proteins show signs of
impaired function, and thereby may contribute to respiratory
muscle dysfunction in patients with COPD. Our findings occur
early in the disease process, because our patients had only mild
to moderate airway obstruction (GOLD I/II).
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